News Related to Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Related coverage linked through entity extraction aliases.

Ultra-Low-Dose Immunotherapy Shows Clinical Activity Across Multiple Trials

May 27, 2026

Three trials show ultra-low-dose checkpoint inhibitors retain efficacy with reduced toxicity and dramatically lower costs. DELII and Patil et al. trials tested low-dose nivolumab in solid tumors and HNSCC; NIVIPIT tested intratumoral low-dose ipilimumab in melanoma.

FDA Approves Monthly Dosing for Rybrevant Faspro in EGFR-Mutated NSCLC, Grants Breakthrough Status

Feb 17, 2026

The FDA has approved a monthly dosing schedule for Rybrevant Faspro in EGFR-mutated NSCLC and granted breakthrough therapy designation for the drug as monotherapy in HPV-unrelated recurrent or metastatic head and neck squamous cell carcinoma after prior therapy.